Scleroderma Foundation's 13th Annual National Patient Education Conference Is Here PDF Print E-mail
Wednesday, 06 July 2011 10:31
Nearly 600 people are anticipated to visit the heart of San Francisco Friday, July 8, through Sunday, July 10, for the Scleroderma Foundation's 13th Annual National Patient Education Conference. Patients, family members, caregivers, doctors and other health care professionals representing 40 states, the District of Columbia, Canada and Mexico will converge at the Hilton San Francisco Union Square for this engaging and educational event that focuses on scleroderma, a rare autoimmune disease.

This year's conference features a variety of workshops hosted by leading scleroderma researchers and medical professionals. Andreas Baxevanis, Ph.D., will give the opening keynote address on the promise of genomics and genome-based personal health care in disease management. James Lemons, Ed.D., will present the closing keynote on "Pain – The Psychology and Physiology: There is Hope." Dr. Baxevanis is Assistant Director for Computational Bioscience, Office of Intramural Research at the National Institutes of Health (NIH), and Associate Investigator, Division of Intramural Research at the National Human Genome Research Institute in Bethesda, Md. Dr. Lemons is the director of The Lemons Center for Behavioral Pain Management in Lenexa, Kan., and a medical psychologist.

Other conference highlights include:
  • Fifty-six workshops and panel discussions for patients, family members and caregivers.
  • Special sessions for children with scleroderma and their families.
  • Representatives from the University of Texas Scleroderma Family Registry and DNA Repository and the University of Texas Southwestern Morphea Registry and DNA Repository will be at the conference seeking interested individuals to serve as donors and controls for scleroderma research.
  • Annual Awards Banquet to honor Scleroderma Foundation members, volunteers and chapters of the Foundation for their dedication and work to advance the mission of the Scleroderma Foundation, and bring awareness to the issues facing the scleroderma patient community.

For more information about scleroderma and the National Patient Education Conference, visit www.scleroderma.org.

 
More articles :

» Role of N-terminal Brain Natriuretic Peptide in Scleroderma-associated Pulmonary Arterial Hypertension

Mark H. Williams, Clive E. Handler, Raza Akram, Colette J. Smith, Clare Das, Joanna Smee, Devaki Nair, Christopher P. Denton, Carol M. Black and John G. CoghlanFirst published online: April 27, 2006Source:

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...

» Gluten - A Health Issue or Just The Latest Fad?

So what's all the fuss about gluten? Is it a real health issue or just the latest fad?Fran Sussman, a holistic practitioner, discussed this issue in a recent online article. As she noted, Gluten is the protein found in wheat, rye, oats, spelt and...

» Shyanne Adams Heading To London Courtesy Of The Make-A-Wish Foundation

It wasn't until Shyanne Adams started feeling better recently that she realized just how hard the past year has been. “I think I was in shock the whole year,” said the 14-year-old Eagle Valley Middle School eighth-grader. “I was depressed. I...

» Autoimmunity Versus Nutrition

Our immune system protects us from various diseases. However, at times it goes into an overdrive and attacks the body itself, leading to tissue destruction and degenerative diseases referred to as autoimmune diseases. Autoimmune disorders include...

» New Study Shows Increased Risk Of Cancer In Scleroderma

patients have a 75% increased risk of cancer compared to the general population, a meta-analysis confirms, leading the authors to recommend screening in these patients.Patients were at particular risk of developing (RR 4.35) and haematological...